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Abstract
Background: Multiple pathogenic factors may contribute to the pathophysiology of Alzheimer’s disease (AD).
Peripheral blood markers have been used to assess biochemical changes associated with AD and mild cognitive
impairment (MCI) and involved in their pathophysiology.
Methods: Plasma samples and clinical data were obtained from participants in the Ansan Geriatric Study (AGE
study). Plasma concentrations of four candidate biomarkers were measured in the normal control (NC), MCI, and
AD group: interleukin-8 (IL-8), IL-10, monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor-a
(TNF-a).
Body mass index (BMI), MMSE (Mini Mental State Examination), CDR(Clinical Dementia Rating) score and
homocystein level were recorded with social and demographic information.
Results: Total of 59 subjects were randomly selected for this analysis [NC (n = 21), MCI(n = 20) and AD(n = 18)]. In
demographic data, educational year was correlated with the diagnosis states (p < 0.0001). No significant differences
in cardiovascular disease, BMI and use of NSAIDs were found in MCI or AD group compared with NC group,
respectively. The involvement of inflammatory illness or conditions in subjects, WBC count, fibrinogen and
homocystein of the three groups, but no significant differences were found in each groups. The plasma IL-8 level
was lower in MCI and AD patients compared with the normal control group (respectively, p < 0.0001). The MCI
and AD patients had similar MCP-1, IL-10, and TNF-a level.
Conclusions: Our study suggests the existence of an independent and negative relationship between plasma IL-8
levels and functional status in MCI and AD patients.
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1. Background
Over the past decade, it has become clear that the brain
maintains intricate relationships with the immune sys-
tem. For example, proteins secreted from the brain can
regulate physiological processes throughout the body
[1]. In Alzheimer’s disease (AD), the characteristic amy-
loid plaques and tangles in the brain are accompanied
by prominent local stimulation of innate immune and
inflammatory responses [2]. The possibility that inflam-
matory cytokines play a role in inflammation in the AD
brain was initially suggested by the observation that the
concentrations of these molecules are increased in AD
tissue and are prominently associated with AD lesions
[3,4]. The inflammatory cytokines are products of acti-
vated microglia and astrocytes, and they stimulate the
phagocytotic activity of microglia. The localization of
cytokines to activated glial cells has been demonstrated
in AD brain tissue by immunohistochemistry [5,6].
Nevertheless, clinical studies of the potential role of
inflammation in AD have yielded inconsistent results.
Whereas several community-based studies have linked
anti-inflammatory interventions to a lowered risk of
developing AD [7], a randomized, placebo-controlled
clinical trial failed to demonstrate a beneficial effect of
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nonsteroidal anti-inflammatory drugs (NSAIDs) on the
progression of AD [8].
Other observational studies that have evaluated the
relationships between markers of systemic inflammation
and AD risk have been inconclusive: circulating cytokines
have been reported to be elevated [9], decreased [10], or
unaltered [11] in AD patients compared with cognitively
intact controls. The observed differences might partly be
explained by differences in the study populations, such as
inclusion criteria or the number of subjects. Nevertheless,
the identification of an inflammatory biomarker of AD is
required to improve the accuracy of diagnosis and moni-
tor disease progression. In addition, it might be useful
diagnostically as an early AD biomarker in combination
with other biological markers [12].
Recent evidence suggests that the pathological process
in AD begins many decades before the appearance of
overt symptoms [13] and that AD rates are predicted to
rise substantially in the coming decades [14]. Conse-
quently, non-invasive, readily accessible peripheral bio-
markers with a high degree of sensitivity and specificity
would be ideal for screening at-risk individuals. In this
study, we examined whether cytokines could be potent
biomarkers for diagnosing AD. We measured the levels
of four candidate biomarkers (IL-8, IL-10, MCP-1 and
TNF-a) in plasma samples and compared them with the
risk of developing AD in Asian subjects.
2. Methods
Study population
Plasma cytokine levels and clinical data were obtained
from participants in the Ansan Geriatric Study (AGE
study) [15,16]. A total of 1,391 subjects (595 men and
796 women) were randomly recruited between Septem-
ber 2004 and March 2006. The follow-up assessment
occurred from 2006 to 2008 (second-wave study; 25.61
± 5.08 months), with uniform, structured follow-up eva-
luations performed by examiners who were blinded to
the collected data. In all, 841 subjects were recruited
randomly from the first-wave study. The second follow-
up sample (n = 600) was recruited between 2008 and
2009. Among the second follow-up group, total of 59
subjects were randomly selected for this analysis.
Informed written consent for participation was obtained
from each individual, and the study protocol was
approved by the institutional review board of the AGE
study. All subjects with recent infections or myocardial
infarction or who had undergone antiplatelet, antihyper-
tensive, antineoplastic, or immunosuppressive drug
treatments were excluded from the study.
Diagnosis of dementia
Dementia was defined according to the diagnostic fea-
tures of dementia given in the Diagnostic and Statistical
Manual of Mental Disorders, fourth edition (DSM-IV)
[17]. The sub-diagnosis of possible or probable Alzhei-
mer’s disease was based on the National Institute of
Neurological and Communicative Disease and Stroke-
Alzheimer’s Disease and Related Disorder Association
(NINCDS-ADRDA) criteria [18]. The diagnosis of mild
cognitive impairment (MCI) was made in accordance
with the clinical criteria of Peterson et al. [19].
Measurements of plasma cytokine concentration
Blood samples were taken from participants after an over-
night fast. Plasma was separated from the blood samples,
and the cytokine concentrations were measured. We mea-
sured IL-8, IL-10, MCP-1, and TNF-a using the BioPlex
cytokine assay (Human Group I assay panel, Bio-Rad, Vee-
nendaal, The Netherlands). In addition, we quantified the
plasma IL-8, IL-10, MCP-1, and TNF-a levels using
enzyme-linked immunosorbent assays (ELISAs) to confirm
the BioPlex data. ELISAs were carried out with the
Human ELISA kit (R&D Systems, Minneapolis, MN, USA)
according to the manufacturer’s instructions.
COX-2 determination by western blot
Platelet proteins were separated in 10% SDS-PAGE and
electroblotted to PVDF membranes in a buffer contain-
ing 0.025 M Tris-HCl, 0.192 M glycine, pH 8.3, at
230 mA for 2 h and 30 min. After blocking with 10%
non-fat milk, immunostaining reaction was performed
with a polyclonal antibody raised against N-terminal of
COX-2 (N-20; Santa Cruz Biotechnology). A peroxidase
conjugate secondary antibody was used (Santa Cruz Bio-
technology). The concentration of the protein was deter-
mined by Bio-Rad Protein Assay (Bio-Rad). Equivalent
amounts of protein (100 μg) were fractionated on 10%
SDS polyacrylamide gel overnight, and proteins were
transferred to nitrocellulose membranes under semidry
conditions. After incubation, the band intensities were
evaluated by bioimaging system (MultiGenius, Syngene,
USA) and bands were quantified on digitized images.
Statistical analyses
Cytokines levels were reported as the mean ± standard
deviation (SD). Independent chi-square test and one-
way analysis of variance (ANOVA) were used to com-
pare diagnosis states. The results were reported sepa-
rately for each group (AD patients and control subjects).
Statistical analysis was performed using SAS ver. 9.1
(SAS Institute, Cary, NC, USA).
3. Results
Table 1 summarizes the demographic factors and clini-
cal characteristics of individual in the normal control
(NC), MCI, and AD group. The three groups were simi-
lar with respect to age and gender. Educational year was
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correlated with the diagnosis states (p <0.0001). How-
ever, no significant differences in cardiovascular disease,
BMI and use of NSAIDs were found in MCI or AD
group compared with NC group, respectively. We also
compared the involvement of inflammatory illness or
conditions in subjects, WBC count, fibrinogen and
homocystein of the three groups, but no significant dif-
ferences were found. IL-8 concentrations are related to
MMSE, disease stage or progression, negatively. The
plasma IL-8 levels in the three study groups are given in
Figure 1. The circulating plasma IL-8 levels were higher
in controls than in MCI and AD patients (respectively,
p < 0.0001). The TNF-a levels were higher in controls
compared to AD patients (p = 0.005). The plasma TNF-
a levels were higher in the control group than in the
MCI patients, but the difference was not significant
(Figure 2). The plasma IL-10 and MCP-1 levels did not
differ among the groups (Figure 3).
Inflammatory process is induced cyclooxygenase-2
(COX-2). The expression of COX-2 is observed a repre-
sentative western blot in each group (Figure 4). The
expression of COX-2 was not changed in patients with
MCI and patients with AD versus control group.
4. Discussion
This study evaluated peripheral markers of inflammation
in elderly patients with MCI or AD and in normal elderly
subjects to assess biochemical changes associated with
AD and MCI and involved in their pathophysiology.
Interleukin-8, a chemokine produced by macrophage
response to proinflammatory mediators such as amyloid,
could be important for recruiting activated microglia
into sites of the brain damaged by AD [20]. CXCR2,
IL-8 receptor, has been localized to dystrophic neurites,
Table 1 Comparison of the demographic characteristics and dementia-related scale scores of the participants
NC (n = 21) MCI (n = 20) AD (n = 18) p-value *Tukey HSD
Age 75.5 ± 1.3 76.1 ± 2.8 75.9 ± 6.0 0.884
Gender 0.954
Male (%) 10 (47.6) 9 (45.0) 9 (50.0)
Female (%) 11 (52.4) 11 (55.0) 9 (50.0)
Educational level (y) 11.6 ± 3.8 6.6 ± 4.9 4.7 ± 4.1 <0.0001 a > b = c
BMI (%) 24.7 ±.2.0 24.9 ± 3.0 22.7 ± 2.3 0.016 a = b > c
CVD (%) 38.1 70.0 33.3 0.044
NSAIDs use (%) 19.1 5.0 11.1 0.423
MMSE 27.9 ± 1.6 24.3 ± 2.6 15.9 ± 6.1 <0.0001 a > b > c
CDR score 0 0.1 ± 0.2 1.1 ± 0.8 <0.0001 a < b = c
GDS score 6.4 ± 3.5 7.2 ± 4.3 8.1 ± 6.7 0.547 a = b = c
WBC (1000/ul) 5.7 ± 1.3 6.4 ± 1.3 6.9 ± 1.4 0.046 a = b < c
Fibrinogen (mg/dL) 318.8 ± 52.4 351.8 ± 67.8 356.3 ± 107.7 0.252 a = b = c
Homocystein (umol) 15.9 ± 5.5 17.7 ± 4.8 19.4 ± 10.7 0.339 a = b = c
Data are expressed as means ± standard deviation unless otherwise indicated.
Independent c2 test and one-way analysis of variance (ANOVA) were used to compare differences between diagnosis states. *Tukey’s Studentized Range (HSD)
Test.
NC: Normal control.
MCI: Mild cognitive impairment.
AD: Alzheimer disease.
BMI: Body mass index
CVD: Cardiovascular diseases.
NSAIDs: Non-steroidal anti-inflammatory drugs.
MMSE: Mini Mental State Examination.
CDR: Clinical Dementia Rating.
WBC: White Blood Cell.


















Figure 1 Plasma levels of IL-8 cytokine from Control (n = 21),
MCI (n = 20), and Alzheimer’s patients (n = 18). Results are
expressed as the mean ± SD. Differences statistically significant
between diagnosis states (* p < 0.0001).
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suggesting that IL-8 mediates glial interactions with
neurons and thereby contributes to neuronal damage
[21]. IL-8 was significantly increased in the cerebrosp-
inal fluid (CSF) in AD compared to controls [22],
whereas the plasma IL-8 level in late-onset AD and vas-
cular dementia did not differ from controls in the Eur-
opean subjects [23]. By contrast, our data showed that
the IL-8 concentration was significantly lower in
patients with MCI or AD compared with the controls.
In addition, the ethnic difference of cytokine levels in
plasma may exist between Asian subjects and European
subjects [24]. However, the levels of COX-2 in the three
studied groups have been detected, which could not
indicate that it is an enzyme which might be induced
with cytokine level. Nevertheless, its diagnostic useful-
ness is shown a dynamic fluctuation between normal
control and AD group. To our knowledge, this is the
first report of a negative relationship between IL-8
plasma levels and functional status in older individuals
affected by AD.
Tumor necrosis factor alpha is a nonspecific, but
potent, factor in the development of several psychiatric
diseases, including depression and dementia [25]. In the
pathogenesis of AD, TNF-a is produced by activated
microglia, mainly in response to the Ab(1-40) and Ab(1-
42) peptides, as well as to oxidative stress [20]. Although
the serum concentrations of TNF-a and the soluble
TNF-a receptor increase with age [26,27], results
regarding the serum TNF-a concentrations in patients
with AD are inconsistent [28-30]. We found decreased
TNF-a levels in the plasma from patients with AD com-
pared with the healthy elderly subjects. We observed a
similar decrease in this biomarker in the MCI group,
but the decrease was not statistically significant com-
pared to the controls.
Monocyte chemoattractant protein-1 is produced by
microglial cells and stimulates astrocytes, which together
participate in the degradation of Ab peptides [20]. Sig-
nificantly increased MCP-1 levels were found in MCI
and mild AD, but not in severe AD patients as com-
pared with controls [31], and evidence indicates that the
plasma MCP-1 levels could serve as biomarkers to
monitor the inflammatory process of AD [32]. We
found elevated MCP-1 levels in the plasma from AD
patients compared with the healthy elderly subjects, but
this increase was not significant.
Interleukin-10 is an anti-inflammatory cytokine in the
central nervous system (CNS) that may function to
reduce inflammation in AD. However, patients with
dementia are reported to have higher mean levels of IL-
10 [33], and an increase in brain IL-10 has been
reported in neurological disease, including AD [34]. In




















Figure 2 Plasma levels of TNF-a cytokine from Control, MCI,
and Alzheimer’s patients. Results are expressed as the mean ± SD.
Differences statistically significant between diagnosis states (** p =
0.005).






































Figure 3 Plasma levels of IL-10 and MCP-1 from control, MCI,
and Alzheimer’s patients. Results are expressed as the mean ± SD.
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this study, IL-10 was the same in the plasma of AD
patients and controls.
The involvement of cytokines in AD is inferred from
several changes in their concentrations in both CSF and
plasma [35,36]. Although whether certain biomarkers
from the brain enter the circulation or vice versa is still
debated, either microglia or other peripheral cells pro-
duce and secrete a wide range of cytokines and chemo-
kines [37]. Circulating cytokines have short half-lives,
they may reach high concentrations at the sites of
release and much lower concentrations after dilution in
blood, and they may circulate bound to molecules that
can prevent their detection by immunological methods
[38]. All of these may contribute to the great variability
in the reported data.
The analysis of these cytokines in these subjects, not
available in severe AD cases, would not allow us to
determine if these alterations are related to the progres-
sion or the severity of the disease. Even though these
data are not sufficient to show a trend of cytokine level’s
alteration according to the progression of disease, it
would be served as preliminary data to develop inflam-
matory biomarker for AD diagnosis.
5. Conclusions
The circulating plasma IL-8 levels were higher in con-
trols than in MCI and AD patients (respectively, p <
0.0001). However, the levels of COX-2 in the three stu-
died groups have been detected, which could not indi-
cate that it is an enzyme which might be induced with
cytokine level. Nevertheless, its diagnostic usefulness is
shown a dynamic fluctuation between normal control
and AD group.
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